An H-I-V drug capable of letting patients live a completely normal life has been added to Australia's Pharmaceutical Benefits Scheme today.
More than 27,500 Australians are currently living with H-I-V.
Now, adults diagnosed with the H-I-V-one infection will be able to easily access the powerful triple-therapy Biktarvy drug.
The single tablet can be taken with or without food and does not require as many of the usual screening tests and monitoring before starting treatment.
Senior specialist from the Albion Centre, Professor Don Smith, says the drug is a huge step forward in the H-I-V treatment globally.
Listen to the full news bulletin in Arabic above
